Nexstim Oyj
5.3.2021 08:01:54 CET | Globenewswire | Press release
Company announcement, Helsinki, 5 March 2021 at 09.00 am (EET)
Nexstim Plc Publishes 2020 Annual Report
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the publication of its 2020 Annual Report. These documents are available on the "Investor Relations" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations.
The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.
NEXSTIM PLC
Mikko Karvinen, CEO
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SBM Offshore Amsterdam B.V.17.11.2026 07:30:00 CET | Press release
SBM Offshore awarded contracts for the Longtail FPSO in Guyana
Azerion Group NV17.11.2026 07:30:00 CET | Press release
Azerion Group N.V. publishes Interim Unaudited Financial Results Q3 and YTD 2026
Rapid Nutrition Plc17.11.2026 05:00:00 CET | Press release
Rapid Nutrition Announces SystemLS AI Mobile App to Accelerate International Growth and Create Recurring Subscription Revenue Opportunity
Novartis Pharma AG17.11.2026 03:43:07 CET | Press release
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
AriBio Co., Ltd.17.11.2026 01:51:42 CET | Press release
AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
